0.00

100.00% -4.85

Genfit Adr (GNFT)

Overview News Price History Discussions Forecast

Genfit Adr stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Previous Close:

$4.85

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$242.51M

Revenue:

Net Income/Loss:

P/E Ratio:

0.00

EPS:

-0.7341

Net Cash Flow:

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$4.9292

Genfit Adr Stock (GNFT) Company Profile

Name

Genfit Adr

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

Address

Employee

125

Twitter

@genfit_pharma

Next Earnings Date

2025-09-22

Latest SEC Filings

GNFT's Discussions on Twitter

Compare GNFT vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GNFT Genfit Adr	0.00	242.51M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	446.64	113.62B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	759.42	82.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	757.02	46.12B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.87	43.60B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	161.88	35.54B	606.42M	-1.28B	-997.58M	-6.403

Genfit Adr Stock (GNFT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-25	Resumed	H.C. Wainwright	Buy
Dec-20-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-23-20	Upgrade	Stifel	Hold → Buy
Jun-25-20	Initiated	BofA/Merrill	Underperform
May-13-20	Downgrade	Kepler	Buy → Reduce
May-12-20	Downgrade	Barclays	Overweight → Equal Weight
May-12-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-29-19	Reiterated	B. Riley FBR	Buy
Jun-25-19	Initiated	Stifel	Hold
Apr-24-19	Initiated	SVB Leerink	Outperform
Apr-22-19	Initiated	Barclays	Overweight